Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

nts With Attention-Deficit/Hyperactivity Disorder (Trial 303)

J. Biederman, M.D.; R. Melmed, M.D.; Anir Patel, M.D.; Keith McBurnett, M.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

APA Poster # NR657

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Interim Results of a Long-Term, Open-Label Study of Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With Attention- Deficit/Hyperactivity Disorder (Trial 305)

F. Sallee, M.D.; J. Biederman, M.D.; J. McGough, M.D.; T. Wigal, Ph.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website: www.shire.com

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties inclu
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/20/2009)...Nov. 20 ,, Reportlinker.com ann...ble in its catalogue. ,, Global Markets for Br...tlinker.com/p0164741/Global-Markets-for-Breast-Bio...m_medium=pr&utm_campaign=prnewswire ,, Th...s the spring loaded core needle market and vacuum ...
(Date:11/20/2009)...Nov. 20 Reportlinker.com announces... its catalogue. ,, Medical Adhesives and Seala...tlinker.com/p0164242/Medical-Adhesives-and-Sealant...amp;utm_medium=pr&utm_campaign=prnewswire ,...aining preeminence in medical devices and equipmen...
(Date:11/20/2009).... 20 Biotel Inc. (OTC Bu...t quarter ended September 30, 2009 with net earnin...enues of $3,263,000. This compares to net earning...nues of $3,168,000 for the first quarter of last y..., Biotel President and CEO Steve Springrose said: ...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Biotel Announced Profitable First Quarter Ended September 30, 2009 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 1Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 4Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 5Siperian to Host Webinar With Panel of Pharmaceutical Experts 57355 1Siperian to Host Webinar With Panel of Pharmaceutical Experts 57355 2Siperian to Host Webinar With Panel of Pharmaceutical Experts 57355 3Siperian to Host Webinar With Panel of Pharmaceutical Experts 57355 4Siperian to Host Webinar With Panel of Pharmaceutical Experts 57355 5Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 1Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 2Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 3Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 4
... SAN MATEO, CA — April 27, 2007 — SciC...nounced that the,following abstracts have been acc...ty of Clinical Oncology in Chicago, Illinois on,Ju...sin alpha 1) Poster,Presentation ,A large first-li...ymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with ...
...NEWTOWN, Pa.--(BUSINESS WIRE)--Apr 30, 2007 - Coll...nnounced that a new,report in the May 2007 issue o...gy evaluating two randomized phase III clinical tr...-inflammatory dose,doxycycline (Oracea(R), 40-mg d...acea. This report has concluded these studies,esta...
Other Medicine Technology:SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4
(Date:11/22/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNewswir...ollowing statement upon the United States Senate,s...ealth Care legislation: ,, "Senators Arlen Spec...ians and all Pennsylvanians for casting stand-up, ...sident Obama,s historic Affordable Health Care Ref...
(Date:11/21/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNews...0s to eliminate onchocerciasis (river blindness) i...lence of the disease in recent years, as evidenced...quiring mass drug administration in six endemic co...annual meeting of the American Society of Tropical...
(Date:11/21/2009)... HAPPYneuron,s most popula... on the iPhone and iPod Touch. , ...9 -- HAPPYneuron,s most popular and addictive game...Pod Touch. Split Words is designed to help banish ...e SplitWords iPhone brain game challenges the br...
(Date:11/20/2009)..., , PRINCETON, NJ, Nov. 20 /PRNewswire-Firs...oday that a Special Meeting of Shareholders will b...f the Meeting is to consider approval of two speci... approve and authorize the sale of all or substant...on the terms provided for in the asset purchase ag...
(Date:11/20/2009)..., , MADISON, N.J., Nov. 20 /PRNewswire-Fi...fluenza virus may have peaked in late October, but...l source of illness in all age groups, including t...gnostics Incorporated (NYSE: DGX ), the world,s ...n and services. ,, In its most recent Quest Di...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...lantable materials that grab stem cells and spur t...g surgeries. Linda Griffith and her colleagues// a...al that could help cells survive the harsh transpl...s. "Creating instructional biomaterials li...
...our-decade long study has come out in support of t...r health. Dutch researchers examined around 1500 m...rs. They have concluded that while drinking les...inked with the lowest rates of deaths. Wine drinke...
...ueensland Health communiqué released yesterday has...ckay. The report has brought to the fore lacunae//...ed heart attacks or hip replacements at Mackay Bas...ompared to other hospitals in the state. A hospi...
...ew survey confirms that pulmonary/critical care ph...ues and are actively managing their patient's slee...ollege of Chest Physicians Sleep Institute (ACCP-S...e therapies to manage their patient's sleep proble...
...YON -- Wet sorghum distiller's grains can be fed i...iciencies, said two researchers//. The two fo...g heifers were conducted by Dr. Mike Brown, a Texa...ulture-Agricultural Research Service animal scient...
...the FDA cannot approve an abbreviated new drug app...thdrawn due to reasons of safety or efficacy// , t...hdrawal before approving any generic version. ...gulatory requirements are met. The FDA added that ...
Other Medicine News:Health News:Healing Bone With Stem Cells 2Health News:Doctors Not Drowsy When Treating Women's Sleep Issues 2Health News:Doctors Not Drowsy When Treating Women's Sleep Issues 3Health News:Wet Distiller's Grains Could Play a Role in Cattle Diets 2Health News:Wet Distiller's Grains Could Play a Role in Cattle Diets 3
...rforming fast, clean, safe and accurate microscopi...processor controlled to automatically spin CenSlid...nd of the cycle, the urine sediment is distributed...alysis.,The CenSlide Urinalysis System contro...
Silicone Foley
Double Pigtail Stent Sets - Sof-Flex®
Sof-Flex® Pediatric Double Pigtail Stent Sets
Medicine Products: